Optimal treatment strategy for Helicobacter pylori: Era of antibiotic resistance

World Journal of Gastroenterology

Volumn 20, Issue 19, 2014, Pages 5654-5659

  Heo, Jun ^a   Jeon, Seong Woo ^a  

^a Kyungpook National University Hospital   (South Korea)

Author keywords

Bacterial eradication; Concomitant therapy; Helicobacter pylori; Hybrid therapy; Standard therapy

Indexed keywords

AMOXICILLIN; BISMUTH; CLARITHROMYCIN; ESOMEPRAZOLE; LANSOPRAZOLE; LEVOFLOXACIN; METRONIDAZOLE; MOXIFLOXACIN; NITROIMIDAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE; TETRACYCLINE; TINIDAZOLE;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL CLEARANCE; DRUG EFFICACY; HELICOBACTER INFECTION; HUMAN; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); POLYMERASE CHAIN REACTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW (TOPIC); TREATMENT OUTCOME; DRUG ADMINISTRATION; DRUG EFFECTS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; MICROBIAL SENSITIVITY TEST;

AMOXICILLIN; BISMUTH; CLARITHROMYCIN; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, BACTERIAL; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; LEVOFLOXACIN; MICROBIAL SENSITIVITY TESTS; POLYMERASE CHAIN REACTION; PROTON PUMP INHIBITORS; TREATMENT OUTCOME;

EID: 84901236170     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i19.5654     Document Type: Article

References (56)

1. Suerbaum S, Michetti P. Helicobacter pylori infection. N Engl J Med 2002; 347: 1175-1186 [PMID: 12374879 DOI: 10.1056/ NEJMra020542]
2. Kim JH, Kim HY, Kim NY, Kim SW, Kim JG, Kim JJ, Roe IH, Seo JK, Sim JG, Ahn H, Yoon BC, Lee SW, Lee YC, Chung IS, Jung HY, Hong WS, Choi KW. Seroepidemiological study of Helicobacter pylori infection in asymptomatic people in South Korea. J Gastroenterol Hepatol 2001; 16: 969-975 [PMID: 11595059]
3. Yim JY, Kim N, Choi SH, Kim YS, Cho KR, Kim SS, Seo GS, Kim HU, Baik GH, Sin CS, Cho SH, Oh BH. Seroprevalence of Helicobacter pylori in South Korea. Helicobacter 2007; 12: 333-340 [PMID: 17669107 DOI: 10.1111/j.1523-5378.2007.00504. x]
4. Malfertheiner P, Megraud F, O'Morain C, Bazzoli F, El-Omar E, Graham D, Hunt R, Rokkas T, Vakil N, Kuipers EJ. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007; 56: 772-781 [PMID: 17170018 DOI: 10.1136/gut.2006.101634]
5. Fock KM, Katelaris P, Sugano K, Ang TL, Hunt R, Talley NJ, Lam SK, Xiao SD, Tan HJ, Wu CY, Jung HC, Hoang BH, Kachintorn U, Goh KL, Chiba T, Rani AA. Second Asia-Pacific Consensus Guidelines for Helicobacter pylori infection. J Gastroenterol Hepatol 2009; 24: 1587-1600 [PMID: 19788600 DOI: 10.1111/j.1440-1746.2009.05982.x]
6. Graham DY, Lu H, Yamaoka Y. A report card to grade Helicobacter pylori therapy. Helicobacter 2007; 12: 275-278 [PMID: 17669098 DOI: 10.1111/j.1523-5378.2007.00518.x]
7. Mégraud F. H pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut 2004; 53: 1374-1384 [PMID: 15306603 DOI: 10.1136/gut.2003.022111]
8. Kobayashi I, Murakami K, Kato M, Kato S, Azuma T, Takahashi S, Uemura N, Katsuyama T, Fukuda Y, Haruma K, Nasu M, Fujioka T. Changing antimicrobial susceptibility epidemiology of Helicobacter pylori strains in Japan between 2002 and 2005. J Clin Microbiol 2007; 45: 4006-4010 [PMID: 17942652 DOI: 10.1128/JCM.00740-07]
9. Kim JJ, Reddy R, Lee M, Kim JG, El-Zaatari FA, Osato MS, Graham DY, Kwon DH. Analysis of metronidazole, clarithromycin and tetracycline resistance of Helicobacter pylori isolates from Korea. J Antimicrob Chemother 2001; 47: 459-461 [PMID: 11266421]
10. Hwang TJ, Kim N, Kim HB, Lee BH, Nam RH, Park JH, Lee MK, Park YS, Lee DH, Jung HC, Song IS. Change in antibiotic resistance of Helicobacter pylori strains and the effect of A2143G point mutation of 23S rRNA on the eradication of H. pylori in a single center of Korea. J Clin Gastroenterol 2010; 44: 536-543 [PMID: 20179610 DOI: 10.1097/ MCG.0b013e3181d04592]
11. Fennerty MB, Kovacs TO, Krause R, Haber M, Weissfeld A, Siepman N, Rose P. A comparison of 10 and 14 days of lansoprazole triple therapy for eradication of Helicobacter pylori. Arch Intern Med 1998; 158: 1651-1656 [PMID: 9701099]
12. Vakil N, Lanza F, Schwartz H, Barth J. Seven-day therapy for Helicobacter pylori in the United States. Aliment Pharmacol Ther 2004; 20: 99-107 [PMID: 15225176 DOI: 10.1111/ j.1365-2036.2004.02029.x]
13. Fuccio L, Minardi ME, Zagari RM, Grilli D, Magrini N, Bazzoli F. Meta-analysis: duration of first-line proton-pump inhibitor based triple therapy for Helicobacter pylori eradication. Ann Intern Med 2007; 147: 553-562 [PMID: 17938394]
14. Dore MP, Graham DY, Mele R, Marras L, Nieddu S, Manca A, Realdi G. Colloidal bismuth subcitrate-based twice-a-day quadruple therapy as primary or salvage therapy for Helicobacter pylori infection. Am J Gastroenterol 2002; 97: 857-860 [PMID: 12003419 DOI: 10.1111/j.1572-0241.2002.05600.x]
15. Lin CK, Hsu PI, Lai KH, Lo GH, Tseng HH, Lo CC, Peng NJ, Chen HC, Jou HS, Huang WK, Chen JL, Hsu PN. Oneweek quadruple therapy is an effective salvage regimen for Helicobacter pylori infection in patients after failure of standard triple therapy. J Clin Gastroenterol 2002; 34: 547-551 [PMID: 11960067]
16. Katelaris PH, Forbes GM, Talley NJ, Crotty B. A randomized comparison of quadruple and triple therapies for Helicobacter pylori eradication: The QUADRATE Study. Gastroenterology 2002; 123: 1763-1769 [PMID: 12454831 DOI: 10.1053/gast.2002.37051]
17. Luther J, Higgins PD, Schoenfeld PS, Moayyedi P, Vakil N, Chey WD. Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: Systematic review and meta-analysis of efficacy and tolerability. Am J Gastroenterol 2010; 105: 65-73 [PMID: 19755966 DOI: 10.1038/ajg.2009.508]
18. Ergül B, Doǧan Z, Sarikaya M, Filik L. The efficacy of twoweek quadruple first-line therapy with bismuth, lansoprazole, amoxicillin, clarithromycin on Helicobacter pylori eradication: a prospective study. Helicobacter 2013; 18: 454-458 [PMID: 24011287 DOI: 10.1111/hel.12086]
19. Ciccaglione AF, Cellini L, Grossi L, Marzio L. Quadruple therapy with moxifloxacin and bismuth for first-line treatment of Helicobacter pylori. World J Gastroenterol 2012; 18: 4386-4390 [PMID: 22969203 DOI: 10.3748/wjg.v18.i32.4386]
20. Fischbach L, Evans EL. Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori. Aliment Pharmacol Ther 2007; 26: 343-357 [PMID: 17635369 DOI: 10.1111/ j.1365-2036.2007.03386.x]
21. Zullo A, Rinaldi V, Winn S, Meddi P, Lionetti R, Hassan C, Ripani C, Tomaselli G, Attili AF. A new highly effective shortterm therapy schedule for Helicobacter pylori eradication. Aliment Pharmacol Ther 2000; 14: 715-718 [PMID: 10848654]
22. Zullo A, Vaira D, Vakil N, Hassan C, Gatta L, Ricci C, De Francesco V, Menegatti M, Tampieri A, Perna F, Rinaldi V, Perri F, Papadìa C, Fornari F, Pilati S, Mete LS, Merla A, Potì R, Marinone G, Savioli A, Campo SM, Faleo D, Ierardi E, Miglioli M, Morini S. High eradication rates of Helicobacter pylori with a new sequential treatment. Aliment Pharmacol Ther 2003; 17: 719-726 [PMID: 12641522]
23. Park HG, Jung MK, Jung JT, Kwon JG, Kim EY, Seo HE, Lee JH, Yang CH, Kim ES, Cho KB, Park KS, Lee SH, Kim KO, Jeon SW. Randomised clinical trial: a comparative study of 10-day sequential therapy with 7-day standard triple therapy for Helicobacter pylori infection in naïve patients. Aliment Pharmacol Ther 2012; 35: 56-65 [PMID: 22066530 DOI: 10.1111/j.1365-2036.2011.04902.x]
24. Paoluzi OA, Visconti E, Andrei F, Tosti C, Lionetti R, Grasso E, Ranaldi R, Stroppa I, Pallone F. Ten and eight-day sequential therapy in comparison to standard triple therapy for eradicating Helicobacter pylori infection: a randomized controlled study on efficacy and tolerability. J Clin Gastroenterol 2010; 44: 261-266 [PMID: 20195162 DOI: 10.1097/ MCG.0b013e3181acebef]
25. Jafri NS, Hornung CA, Howden CW. Meta-analysis: sequential therapy appears superior to standard therapy for Helicobacter pylori infection in patients naive to treatment. Ann Intern Med 2008; 148: 923-931 [PMID: 18490667]
26. Gatta L, Vakil N, Leandro G, Di Mario F, Vaira D. Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children. Am J Gastroenterol 2009; 104: 3069-3079; quiz 1080 [PMID: 19844205 DOI: 10.1038/ajg.2009.555]
27. Zullo A, Hassan C, Ridola L, De Francesco V, Vaira D. Standard triple and sequential therapies for Helicobacter pylori eradication: an update. Eur J Intern Med 2013; 24: 16-19 [PMID: 22877993 DOI: 10.1016/j.ejim.2012.07.006]
28. Murakami K, Fujioka T, Okimoto T, Sato R, Kodama M, Nasu M. Drug combinations with amoxycillin reduce selection of clarithromycin resistance during Helicobacter pylori eradication therapy. Int J Antimicrob Agents 2002; 19: 67-70 [PMID: 11814770]
29. De Francesco V, Margiotta M, Zullo A, Hassan C, Troiani L, Burattini O, Stella F, Di Leo A, Russo F, Marangi S, Monno R, Stoppino V, Morini S, Panella C, Ierardi E. Clarithromycinresistant genotypes and eradication of Helicobacter pylori. Ann Intern Med 2006; 144: 94-100 [PMID: 16418408]
30. Vaira D, Zullo A, Vakil N, Gatta L, Ricci C, Perna F, Hassan C, Bernabucci V, Tampieri A, Morini S. Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a randomized trial. Ann Intern Med 2007; 146: 556-563 [PMID: 17438314]
31. Summaries for patients. Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication. Ann Intern Med 2007; 146: I20 [PMID: 17438311]
32. Essa AS, Kramer JR, Graham DY, Treiber G. Meta-analysis: four-drug, three-antibiotic, non-bismuth-containing "concomitant therapy" versus triple therapy for Helicobacter pylori eradication. Helicobacter 2009; 14: 109-118 [PMID: 19298338 DOI: 10.1111/j.1523-5378.2009.00671.x]
33. Gisbert JP, Calvet X. Review article: non-bismuth quadruple (concomitant) therapy for eradication of Helicobater pylori. Aliment Pharmacol Ther 2011; 34: 604-617 [PMID: 21745241 DOI: 10.1111/j.1365-2036.2011.04770.x]
34. Gisbert JP, Calvet X, O'Connor A, Mégraud F, O'Morain CA. Sequential therapy for Helicobacter pylori eradication: a critical review. J Clin Gastroenterol 2010; 44: 313-325 [PMID: 20054285 DOI: 10.1097/MCG.0b013e3181c8a1a3]
35. Wu DC, Hsu PI, Wu JY, Opekun AR, Kuo CH, Wu IC, Wang SS, Chen A, Hung WC, Graham DY. Sequential and concomitant therapy with four drugs is equally effective for eradication of H pylori infection. Clin Gastroenterol Hepatol 2010; 8: 36-41. e1 [PMID: 19804842 DOI: 10.1016/j.cgh.2009.09.030]
36. Hsu PI, Wu DC, Wu JY, Graham DY. Modified sequential Helicobacter pylori therapy: proton pump inhibitor and amoxicillin for 14 days with clarithromycin and metronidazole added as a quadruple (hybrid) therapy for the final 7 days. Helicobacter 2011; 16: 139-145 [PMID: 21435092 DOI: 10.1111/j.1523-5378.2011.00828.x]
37. Molina-Infante J, Romano M, Fernandez-Bermejo M, Federico A, Gravina AG, Pozzati L, Garcia-Abadia E, Vinagre-Rodriguez G, Martinez-Alcala C, Hernandez-Alonso M, Miranda A, Iovene MR, Pazos-Pacheco C, Gisbert JP. Optimized nonbismuth quadruple therapies cure most patients with Helicobacter pylori infection in populations with high rates of antibiotic resistance. Gastroenterology 2013; 145: 121-128. e1 [PMID: 23562754 DOI: 10.1053/j.gastro.2013.03.050]
38. Huang YK, Wu MC, Wang SS, Kuo CH, Lee YC, Chang LL, Wang TH, Chen YH, Wang WM, Wu DC, Kuo FC. Lansoprazole-based sequential and concomitant therapy for the firstline Helicobacter pylori eradication. J Dig Dis 2012; 13: 232-238 [PMID: 22435509 DOI: 10.1111/j.1751-2980.2012.00575.x]
39. McNicholl AG, Marin AC, Molina-Infante J, Castro M, Barrio J, Ducons J, Calvet X, de la Coba C, Montoro M, Bory F, Perez-Aisa A, Forné M, Gisbert JP. Randomised clinical trial comparing sequential and concomitant therapies for Helicobacter pylori eradication in routine clinical practice. Gut 2014; 63: 244-249 [PMID: 23665990 DOI: 10.1136/gutjnl-2013-304820]
40. Lim JH, Lee DH, Choi C, Lee ST, Kim N, Jeong SH, Kim JW, Hwang JH, Park YS, Lee SH, Shin CM, Jo HJ, Jang ES, Song Is, Jung HC. Clinical outcomes of two-week sequential and concomitant therapies for Helicobacter pylori eradication: a randomized pilot study. Helicobacter 2013; 18: 180-186 [PMID: 23305083 DOI: 10.1111/hel.12034]
41. Zullo A, Scaccianoce G, De Francesco V, Ruggiero V, D' Ambrosio P, Castorani L, Bonfrate L, Vannella L, Hassan C, Portincasa P. Concomitant, sequential, and hybrid therapy for H. pylori eradication: a pilot study. Clin Res Hepatol Gastroenterol 2013; 37: 647-650 [PMID: 23747131 DOI: 10.1016/ j.clinre.2013.04.003]
42. Sardarian H, Fakheri H, Hosseini V, Taghvaei T, Maleki I, Mokhtare M. Comparison of hybrid and sequential therapies for Helicobacter pylori eradication in Iran: a prospective randomized trial. Helicobacter 2013; 18: 129-134 [PMID: 23121338 DOI: 10.1111/hel.12017]
43. Malfertheiner P, Megraud F, O'Morain CA, Atherton J, Axon AT, Bazzoli F, Gensini GF, Gisbert JP, Graham DY, Rokkas T, El-Omar EM, Kuipers EJ. Management of Helicobacter pylori infection--the Maastricht IV/ Florence Consensus Report. Gut 2012; 61: 646-664 [PMID: 22491499 DOI: 10.1136/gutjnl-2012-302084]
44. Rokkas T, Sechopoulos P, Robotis I, Margantinis G, Pistiolas D. Cumulative H. pylori eradication rates in clinical practice by adopting first and second-line regimens proposed by the Maastricht III consensus and a third-line empirical regimen. Am J Gastroenterol 2009; 104: 21-25 [PMID: 19098844 DOI: 10.1038/ajg.2008.87]
45. Lee JM, Breslin NP, Hyde DK, Buckley MJ, O'Morain CA. Treatment options for Helicobacter pylori infection when proton pump inhibitor-based triple therapy fails in clinical practice. Aliment Pharmacol Ther 1999; 13: 489-496 [PMID: 10215733]
46. Gisbert JP, Gisbert JL, Marcos S, Jimenez-Alonso I, Moreno-Otero R, Pajares JM. Empirical rescue therapy after Helicobacter pylori treatment failure: a 10-year single-centre study of 500 patients. Aliment Pharmacol Ther 2008; 27: 346-354 [PMID: 17999716 DOI: 10.1111/j.1365-2036.2007.03573.x]
47. Lee BH, Kim N, Hwang TJ, Lee SH, Park YS, Hwang JH, Kim JW, Jeong SH, Lee DH, Jung HC, Song IS. Bismuthcontaining quadruple therapy as second-line treatment for Helicobacter pylori infection: effect of treatment duration and antibiotic resistance on the eradication rate in Korea. Helicobacter 2010; 15: 38-45 [PMID: 20302588 DOI: 10.1111/ j.1523-5378.2009.00735.x]
48. Shehada S, Srugo I, Shaoul R. Failure of sequential therapy to eradicate Helicobacter pylori in previously treated subjects. Helicobacter 2007; 12: 645-647 [PMID: 18001409 DOI: 10.1111/j.1523-5378.2007.00558.x]
49. Gisbert JP, Gisbert JL, Marcos S, Moreno-Otero R, Pajares JM. Third-line rescue therapy with levofloxacin is more effective than rifabutin rescue regimen after two Helicobacter pylori treatment failures. Aliment Pharmacol Ther 2006; 24: 1469-1474 [PMID: 17032282 DOI: 10.1111/j.1365-2036.2006.03149.x]
50. Gatta L, Zullo A, Perna F, Ricci C, De Francesco V, Tampieri A, Bernabucci V, Cavina M, Hassan C, Ierardi E, Morini S, Vaira D. A 10-day levofloxacin-based triple therapy in patients who have failed two eradication courses. Aliment Pharmacol Ther 2005; 22: 45-49 [PMID: 15963079 DOI: 10.1111/ j.1365-2036.2005.02522.x]
51. Manfredi M, Bizzarri B, de'Angelis GL. Helicobacter pylori infection: sequential therapy followed by levofloxacincontaining triple therapy provides a good cumulative eradication rate. Helicobacter 2012; 17: 246-253 [PMID: 22759323 DOI: 10.1111/j.1523-5378.2012.00945.x]
52. Gisbert JP, Molina-Infante J, Marin AC, Vinagre G, Barrio J, McNicholl AG. Second-line rescue triple therapy with levofloxacin after failure of non-bismuth quadruple "sequential" or "concomitant" treatment to eradicate H. pylori infection. Scand J Gastroenterol 2013; 48: 652-656 [PMID: 23556551 DOI: 10.3109/00365521.2013.786132]
53. Hsu PI, Chen WC, Tsay FW, Shih CA, Kao SS, Wang HM, Yu HC, Lai KH, Tseng HH, Peng NJ, Chen A, Kuo CH, Wu DC. Ten-day Quadruple therapy comprising proton-pump inhibitor, bismuth, tetracycline, and levofloxacin achieves a high eradication rate for Helicobacter pylori infection after failure of sequential therapy. Helicobacter 2014; 19: 74-79 [PMID: 24033865 DOI: 10.1111/hel.12085]
54. Noreddin AM, Marras TK, Sanders K, Chan CK, Hoban DJ, Zhanel GG. Pharmacodynamic target attainment analysis against Streptococcus pneumoniae using levofloxacin 500 mg, 750 mg and 1000 mg once daily in plasma (P) and epithelial lining fluid (ELF) of hospitalized patients with community acquired pneumonia (CAP). Int J Antimicrob Agents 2004; 24: 479-484 [PMID: 15519481 DOI: 10.1016/j.ijantimica g.2004.06.010]
55. Furuta T, Sagehashi Y, Shirai N, Sugimoto M, Nakamura A, Kodaira M, Kenmotsu K, Nagano M, Egashira T, Ueda K, Yoneyama M, Ohashi K, Ishizaki T, Hishida A. Influence of CYP2C19 polymorphism and Helicobacter pylori genotype determined from gastric tissue samples on response to triple therapy for H pylori infection. Clin Gastroenterol Hepatol 2005; 3: 564-573 [PMID: 15952098]
56. Giorgio F, Principi M, De Francesco V, Zullo A, Losurdo G, Di Leo A, Ierardi E. Primary clarithromycin resistance to Helicobacter pylori: Is this the main reason for triple therapy failure? World J Gastrointest Pathophysiol 2013; 4: 43-46 [PMID: 23946886 DOI: 10.4291/wjgp.v4.i3.43]